Anirban Maitra, Laura and Isaac Perlmutter Professor of Pathology and Director of the Perlmutter Cancer Center, shared on X:
“Congratulations Dr. Neeha Zaidi, S. Daniel Haldar, MD, Dr. Elizabeth Jaffee and team!
This is the 1st study to demonstrate the feasibility of mutant KRAS targeted vaccine – not in established Pancreatic Cancer – but in high risk individuals, with persistent T cells ~2years!”
Title: First-in-human testing of a mutant KRAS vaccine for pancreatic cancer interception in high-risk cohorts
Authors: S. Daniel Haldar, Amanda L. Huff, Hejia Henry. Wang, Zirui Zhu, Maureen Berg, Jiayun Lu, Nancy Sun, Elizabeth Abou Diwan, Hassan Sinan, Christopher J. Thoburn, Matthew Z. Guo, Takeichi Yoshida, Linda C. Chu, Anna K. Ferguson, Dimitrios N. Sidiropoulos, Luciane T. Kagohara, Won Jin. Ho, Katherine M. Bever, Marina Baretti, Mark Yarchoan, Daniel A. Laheru, Julie M. Nauroth, Amy M. Thomas, Hao Wang, Nilofer Saba. Azad, Michael G. Goggins, Elizabeth M. Jaffee, Neeha Zaidi
Other articles about pancreatic cancer on OncoDaily.